Findings

What do systematic reviews say?

3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%

Opioids vs placebo or no treatment

Duration of mechanical ventilation · neonates with mechanical ventilation

1 finding from 1 review

Opioids for newborn infants receiving mechanical ventilation 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1259 participants
Moderate

Morphine vs diamorphine

Duration of mechanical ventilation · neonates with mechanical ventilation

The review found no eligible studies for this question.

1 finding from 1 review

Opioids for newborn infants receiving mechanical ventilation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fentanyl vs sufentanil

Duration of mechanical ventilation · neonates with mechanical ventilation

1 finding from 1 review

Opioids for newborn infants receiving mechanical ventilation 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Fentanyl vs remifentanil

Duration of mechanical ventilation · neonates with mechanical ventilation

The review found no eligible studies for this question.

1 finding from 1 review

Opioids for newborn infants receiving mechanical ventilation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Opioids vs other analgesics and sedatives

Duration of mechanical ventilation · neonates with mechanical ventilation

1 finding from 1 review

Opioids for newborn infants receiving mechanical ventilation 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Very low

Palivizumab vs Placebo, no intervention or usual care (with or without placebo)

Number of wheezing days · children (0 to 24 months)

Palivizumab leads to lower number of wheezing days compared with placebo, no intervention or standard care (high certainty).

1 finding from 1 review

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children 2021 · Cochrane Headline outcomes only
RR 0.39 [0.35, 0.44]
1 study · 429 participants
High

Blue light vs white light

Surgical complications, serious (up to 90 days; MCID 2%) · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in surgical complications, serious (up to 90 days; MCID 2%) compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 0.54 [0.14, 2.14]
1 study · 525 participants
Low

Blue light vs white light

Any adverse events (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

Blue light showed no clear difference in any adverse events (up to 90 days; MCID 5%) compared with white light (low certainty).

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
RR 1.09 [0.88, 1.33]
3 studies · 1375 participants
Low

Blue light vs white light

Surgical complications, non‐serious (up to 90 days; MCID 5%) · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab/etesevimab vs placebo

Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Mortality by day 60 · non‐hospitalised individuals with COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sotrovimab vs placebo

Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Mortality by day 60Â · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Mortality by day 90 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in mortality by day 90 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
HR 1.09 [0.49, 2.43]
1 study · 314 participants
Low

Bamlanivimab vs placebo

Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)

It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.17 [0.75, 1.85]
1 study · 311 participants
Very low

Bamlanivimab vs placebo

Time to hospital discharge · hospitalised individuals with COVID‐19 (moderate to severe disease)

Bamlanivimab showed no clear difference in time to hospital discharge up to 26.10.2020, absolute effects for… compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
HR 0.97 [0.76, 1.18]
1 study · 314 participants
Low

Casirivimab/imdevimab vs usual care

Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azithromycin vs placebo or usual care

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…

Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.98 [0.9, 1.06]
4 studies · 8600 participants
High

Azithromycin vs placebo or usual care

Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.03 [0.95, 1.12]
1 study · 138 participants
Low